Abstract
In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Clinical Trials, Phase III as Topic
-
Humans
-
Imidazoles / adverse effects
-
Imidazoles / therapeutic use*
-
Immunotherapy / trends*
-
Lymphatic Metastasis
-
Melanoma / drug therapy*
-
Melanoma / immunology
-
Melanoma / pathology
-
Neoplasm Staging
-
Oximes / adverse effects
-
Oximes / therapeutic use*
-
Progression-Free Survival
-
Pyridones / administration & dosage
-
Pyridones / therapeutic use*
-
Pyrimidinones / administration & dosage
-
Pyrimidinones / therapeutic use*
-
Sentinel Lymph Node / drug effects
-
Sentinel Lymph Node / pathology
Substances
-
Imidazoles
-
Oximes
-
Pyridones
-
Pyrimidinones
-
trametinib
-
dabrafenib